

Fax Referral To:
814-283-2211

Phone 855-265-8008



1333 Plank Road, Suite 200, Duncansville, PA 16635
Dermatology Enrollment Form

Ship to: Patient Office Other

Date: _____ Needs by date: _____

Is patient new to this therapy?
 YES NO

Documents necessary for facilitation of referral: Enrollment form Front/Back copies of all insurance/prescription cards Labwork and medication profile

PATIENT INFORMATION

(Complete the following or send patient demographic sheet)

Patient Name: _____
Address: _____
City, State, Zip: _____
Home Phone: _____
Alternate Phone: _____
SS #: _____
Date of Birth: _____ Gender: _____

PRESCRIBER INFORMATION

Prescriber's Name: _____
NPI #: _____
DEA #: _____ State License #: _____
Group or Hospital: _____
Address: _____
City, State Zip: _____
Phone: _____ Fax: _____
Contact Person: _____ Phone: _____

Diagnosis:

Additional Clinical Information:

Please include diagnosis name and ICD-10:

Weight: _____ kg/lbs • Height: _____ in/cm

Allergies: _____
Failed Therapies/Dates: _____

INJECTION TRAINING

MD to coordinate Value Specialty Pharmacy to coordinate

<input type="checkbox"/> Cimzia (PsA)	<input type="checkbox"/> 200mg/ml prefilled syringe <input type="checkbox"/> 200mg/ml vial	<input type="checkbox"/> Induction: Inject 400mg subcutaneously on days 0, 14, 28 <input type="checkbox"/> Maintenance: Inject 400mg subcutaneously every 28 days <input type="checkbox"/> Maintenance: Inject 200mg subcutaneously every 14 days
<input type="checkbox"/> Cosentyx	<input type="checkbox"/> 150mg pen <input type="checkbox"/> 150mg prefilled syringe	<input type="checkbox"/> Induction: 300mg (2 x 150mg) subcutaneously at weeks 0,1,2,3,4 <input type="checkbox"/> Maintenance: Inject 300mg (2 x 150mg) subcutaneously every 28 days
<input type="checkbox"/> Enbrel	<input type="checkbox"/> 50mg/ml prefilled syringe <input type="checkbox"/> 50mg/ml Sureclick autoinjector	<input type="checkbox"/> Induction: Inject 50mg subcutaneously twice weekly x 3 months <input type="checkbox"/> Maintenance: Inject 50mg subcutaneously every 7 days
<input type="checkbox"/> Humira	<input type="checkbox"/> 40mg/0.8ml pen <input type="checkbox"/> 40mg/0.8ml prefilled syringe	<input type="checkbox"/> Induction: Inject 80mg subcutaneously on Day 1, then 40mg subcutaneously on Day 8 then 40mg subcutaneously on Day 22 <input type="checkbox"/> Maintenance: Inject 40mg subcutaneously every 14 days
<input type="checkbox"/> Otezla	<input type="checkbox"/> 10mg/20mg/30mg starter pack <input type="checkbox"/> 30mg	<input type="checkbox"/> Titration Schedule: Day 1-10mg in AM, Day 2- 10mg twice daily, Day 3 – 10mg in AM, 20mg in PM, Day 4 – 20mg twice daily, Day 5 – 20mg in AM, 30mg in PM, then 30mg twice daily <input type="checkbox"/> 30mg twice daily
<input type="checkbox"/> Simponi (PsA)	<input type="checkbox"/> 50mg/0.5ml syringe <input type="checkbox"/> 50mg/0.5ml autoinjector	<input type="checkbox"/> Inject 50mg subcutaneously every 28 days
<input type="checkbox"/> Stelara	<input type="checkbox"/> 45mg/0.5ml prefilled syringe (<100kg) <input type="checkbox"/> 90mg/ml prefilled syringe (>100kg)	<input type="checkbox"/> Induction: Inject _____ mg subcutaneously at days 0 and 28 <input type="checkbox"/> Maintenance: Inject _____ mg subcutaneously every 84 days (12wks)

QUANTITY AND REFILLS:

Dispense # _____ with _____ refills.

My signature below authorizes Value Specialty Pharmacy staff to act as my authorized agent to complete the insurance prior authorization process for my patient listed above. My authorization shall include any required signatures by Value Specialty Pharmacists on my behalf to facilitate this process and acknowledge their authorized access to necessary healthcare data to complete said processes.

Physician Signature _____

This prescription will be filled generically unless prescriber writes "DAW" in the box to the right

